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(PDI) for ten of the plans, and by independent dose 
calculation checks using RadCalc (RadCalc Version 6.2, 
LifeLine Software Inc, Tyler, USA). 
 
Results: The observed differences between the conventional 
and the IMRT plans were limited. In average the maximum 
dose was 0.3 percentage points (pp) lower for IMRT than for 
conventional plans. The ITV coverage was better for the IMRT 
plans, with an average ITV minimum dose of 95.9 % compared 
to 94.1% (+1.8 pp). However, the PTV coverage was slightly 
worse for the IMRT plans, a decrease of 0.4 pp in V95%. The 
only relevant organs at risk are the lenses, were the 
maximum dose on average were lowered 0.3 Gray and the 
mean dose on average was lowered 0.1 Gray. The average HI 
for the IMRT plans was 4.0 while 5.1 for the conventional 
plans. The 10 PDI measurements were all accepted with a 
reference gamma index value of 5% dose agreement within 3 
mm distance to agreement, and no further measurements 
were performed. Independent dose calculation checks were 
performed for QA. The time spend on treatment planning was 
approximately 20 minutes for IMRT plans and could easily be 
up to 3 hours when using the conventional technique. 
 
 
Conclusion: It was possible to significantly reduce the time 
spend on dose planning by changing the treatment technique 
from conventional to IMRT for PCI patients while attaining 
comparable dosimetric quality of the treatment plans. 
Furthermore, both the treatment time and the time spend on 
quality assurances are comparable for the two techniques. 
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Purpose or Objective: To illustrate the technique and 
outcome of stereotactic body radiation therapy (SBRT) using 
Tomotherapy for refractory bone pain from metastatic 
disease. Tomotherapy SBRT planning parameters and 
dosimetric evaluation are outlined. 
 
Material and Methods: In 2013, a 70 year old female patient 
presented with metastatic non-small cell lung carcinoma, 
following resection of lung primary in 2012. CT and MRI 
confirmed a lytic lesion on right of sacrum. Patient’s sacrum 
initially treated with 30Gy/10Fx. Pain recurred 2 months post 
RT and managed by palliative care. 6 months post RT patient 
returned for consideration of re-treatment. Pain was 
refractory to everything apart from 15mg of oxycodone every 
hour. RO discussed the patient and risks of re-irradiation 
within the multidisciplinary setting. The consensus was to 
offer the patient SBRT, 24Gy in 3 fractions to the sacrum.  
Helical Tomotherapy was used to plan and treat patient. The 
irregular PTV volume was 201.12cm3. Dose volume 
constraints included: colon (0.035cc<18.4Gy, 20cc<14.3Gy), 
sacral plexus (0.035cc<11Gy, 5cc<7Gy), cauda equina 
(0.035cc<16Gy, 5cc<14Gy), and skin (0.035cc<26Gy, 
10cc<23Gy). No hotspots were to be located over the nerve 
roots. 
 
Results: Tomotherapy planning parameters included field 
width of 2.5cm, pitch of 0.2 and a modulation factor of 1.5. 
Beam on time was 400.3 seconds. PTV coverage statistics 
were D99 = 22.5Gy (93.75%), V95 = 98.57%, VTD = 90.53%, 
Median = 25.37Gy (105.71%), D1 = 27.8Gy (115.83%). OAR 
dose included colon 0.035cc = 8.1Gy, 20cc = 6.8Gy; sacral 
plexus 0.035cc = 27.3Gy, 5cc = 25.3Gy; cauda equina 0.035 = 
26.2Gy, 5cc = 21Gy; skin 0.035cc = 15.4Gy, 10cc = 12.3Gy. 
The conformity index statistics were R100% = 0.97, V105% 
outside PTV = 2cc, R50% = 4.21, Dmax > 2cm from PTV = 
16.45Gy (68.5%).  
One week post SBRT, patient’s pain stable and mobility 
improving. Whole body bone scan 2 months post SBRT showed 
decreased activity and size of sacral lesion. 4 months post 
SBRT patient returned with significant left sacral pain with 
concern of further metastatic disease. PET confirmed no 
uptake in left sacrum. Pain associated with insufficiency 
fracture with cause unknown, SBRT or bone metastasis likely 
contributors. 5 months post SBRT patient improved 
dramatically, completely ambulant with PET/CT showing no 
evidence of recurrence/metastatic disease. 13 months post 
SBRT, patient remains asymptomatic, CT shows no evidence 
of metastatic disease. 
 
Conclusion: This case study illustrates how the use SBRT can 
result in pain control for patients with refractory metastatic 
bone pain where there may be no other options available 
apart from palliative care, even in cases where the 
treatment volume is relatively large. This data is also 
informative since the patient shows no definite evidence of 
metastatic disease. Further studies could lead to improved 
therapies for the control of metastatic bone pain. 
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Purpose or Objective: Proton therapy cancer treatment 
offer potential clinical advantages compared with photon 
radiation therapy for many cancer sites. However, the 
treatment cost with proton is much higher than with 
conventional radiation. The objective of this study is to 
discuss how to improve a procedure, already described by 
others worldwide, to provide quantitative clues to select the 
patient for proton treatment instead of photon. 
 
Material and Methods: The respective medical and clinical 
benefits of proton and photon therapy are assessed by in 
silico comparison following four successive steps. First, the 
dosimetric analysis is made using parameters derived from 
dose volume histogram (DVH) for target volume and organs at 
risks. Second, the DVHs are exported from TPS to calculate 
TCP and mostly NTCP radiobiological indexes. In the third 
step, a statistical comparison is done using non-parametric 
test to calculate p-value, then bootstrap method is used to 
estimate the confidence intervals including the lower and 
upper limit of agreements. Then the correlation between 
data from proton and photon treatment planning is assessed 
using Spearman’s rank test. Finally, the cost-effectiveness 
and quality adjusted life years (QALYs) can be used to 
measures the outcome of the therapy and check if the 
therapeutic gain of proton therapy worth the increased 
expenses of it versus photon. 
 
Results: The results with in silico data can be taken into 
account to make a proposal of a decisional procedure. The 
dosimetric and radiobiological analysis can be used to check 
the medical benefit with either proton or photon. The 
statistical tests allow to check if the dosimetric or 
radiobiological benefits for a specific patient can be included 
in the confidence interval of agreement of a representative 
population, the most homogenous possible. A Markov model 
can be used to simulate the life of patients treated with 
proton / photon radiation. The virtual evaluation may 
indicate for which cancer sites proton therapy could be more 
cost-effective than photon therapy. 
 
Conclusion: The introduction of model based clinical trials 
with the possibility of individual assessment is a coming 
approach well adapted to the fast improvement of medical 
technology. The presently rising offer of proton therapy is a 
good example. The QALY concept based on objective 
dosimetric and clinical expected / modelized outcome may 
be a valuable response to this new challenge. However, large 
